Cagrilintide Dosage Chart: 45 Trials, One Sponsor, No Approval
Summary: A genuine late-stage pharmaceutical programme rather than a research chemical with a rumour attached, which changes what its numbers are and where they come from.
This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.
Cagrilintide is not in the same category as most compounds discussed alongside it. It is an amylin analogue in late-stage pharmaceutical development, and the registry makes that unusually clear.
The numbers behind the programme
ClinicalTrials.gov lists roughly 45 studies under the name. The phase distribution is what a real development programme looks like:
| Phase | Studies |
|---|---|
| Phase 3 | 22 |
| Phase 1 | 17 |
| Phase 2 | 6 |
About 25 are recorded as completed, with a further ten recruiting and seven active but not recruiting.
One detail is worth more than the counts: every one of those 45 studies lists Novo Nordisk as lead sponsor. Not a single independent or academic entry appears. That is a single-company programme from Phase 1 through Phase 3.
What a single sponsor tells you
Two things, pulling in opposite directions, and both are true.
It is a mark of seriousness. Running 22 Phase 3 studies is enormously expensive, and companies do not do it speculatively. The compound has been through dose-finding, has a defined mechanism as an amylin analogue, and is being developed for a specific indication rather than sold on a forum.
It also means the entire evidence base has one owner. No independent group has replicated the findings, because no independent group has run a study. That is normal for a drug in development and it is still a limitation worth naming, particularly when figures from the programme circulate outside it.
Why there is no approved dose
No regulator has approved cagrilintide. A Phase 3 programme in progress and an approved product are different states, and only the second produces a label with authorised quantities.
So a cagrilintide dosage chart is restating quantities used in trials rather than quantities anybody authorised. That is a legitimate thing to publish when it says so. The trial figures are real, measured and published, and they belong to protocols with defined populations and endpoints.
What to check on any chart for it
Whether the figures are attributed to a trial rather than presented as a recommendation. Whether the chart distinguishes cagrilintide alone from its use combined with semaglutide, which is a different exposure with a different rationale. And whether it notes that the compound remains unapproved, because a late-stage programme reads a lot like an approval to anyone skimming.